根据《中华人民共和国公司法》、《中华人民共和国证券法》、《国有企业、 上市公司选聘会计师事务所管理办法》、《深圳证券交易所上市公司自律监管指 引第1号——主板上市公司规范运作》及《哈尔滨三联药业股份有限公司章程》 等规定和要求，哈尔滨三联药业股份有限公司（以下简称"公司"）董事会审计 委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对会 计师事务所2024年度履职评估及履行监督职责的情况汇报如下： 一、2024年年审会计师事务所基本情况 （一）会计师事务所基本情况 中兴财光华会计师事务所（特殊普通合伙）（以下简称"中兴财光华"）成 立于1999年1月，2013年11月转制为特殊普通合伙，注册地址为北京市西城区阜 成门外大街2号22层A24，首席合伙人为姚庚春。截至2024年末，中兴财光华共有 合伙人187人，注册会计师804人，其中331人签署过证券服务业务审计报告。 （二）聘任会计师事务所履行的程序 哈尔滨三联药业股份有限公司 董事会审计委员会对会计师事务所 2024年度履职情况评估及履行监督职责情况的报告 在执行审计工作的过程中，中兴财光华就会计师事务所和相关审计人员的独 立性、审计工作 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-022 哈尔滨三联药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 本次会计政策变更是根据财政部发布的相关企业会计准则解释而进行的相 应变更，不会对公司财务状况、经营成果和现金流量产生重大影响。 哈尔滨三联药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开 第四届董事会第二十一次会议，审议通过了《关于会计政策变更的议案》，根据 《深圳证券交易所股票上市规则》《公司章程》等有关规定，本次会计政策变更 无需提交公司股东大会审议，现将具体情况公告如下： 一、本次会计政策变更概述 1、会计政策变更原因 2024 年 12 月，财政部发布《企业会计准则解释第 18 号》（财会〔2024〕24 号），规定对于不属于单项履约义务的保证类质量保证产生的预计负债进行会计 核算时，应当按确定的预计负债金额，借记"主营业务成本、其他业务成本"等 科目，贷记"预计负债"科目，该解释规定自印发之日起施行，允许企业自发布 年度提前执行。 2、变更前公司采用的会计政策 本次会计 ...

立董事任职管理要求。 哈尔滨三联药业股份有限公司 独立董事关于独立性自查情况的报告 本人刘洪泉作为哈尔滨三联药业股份有限公司（以下简称"公司"）独立董 事，在 2024 年度任职期间恪尽职守、忠实履职，切实维护了中小投资者的利益， 符合《上市公司独立董事管理办法》等相关规定的独立性要求，现将本人 2024 年度独立性自查情况报告如下： | 事项 | 自查结果 | | --- | --- | | 1、本人及配偶、父母、子女及其主要社会关系，是否在本公司或 | ☑否 | | 附属企业任职？ | □是：请详细说明。 | | 2、本人及配偶、父母、子女是否直接或者间接持有上市公司股份 | ☑否 | | 比例 1%以上？ | □是：请详细说明。 | | 3、本人及配偶、父母、子女是否为上市公司前 10 名股东中的自 | ☑否 | | 然人股东？ | □是：请详细说明。 | | 4、本人及配偶、父母、子女是否在持股 5%以上股东单位或本公 | ☑否 | | 司前五名股东单位任职？ | □是：请详细说明。 | | 5、本人及配偶、父母、子女是否在本公司控股股东、实际控制人 | ☑否 | | 的附属企业任职？ | □是：请详 ...

哈三联（002900）公告，2025年第一季度营收为2.05亿元，同比下降16.93%；净亏损2884.51万元，去 年同期净利润1878.95万元。 ...

Investment Rating - The report indicates a positive outlook for the weight loss drug sector within the pharmaceutical and biotechnology industry, suggesting potential acceleration in business development (BD) opportunities [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of -0.36% from April 14 to April 18, underperforming compared to the Wind All A index (0.39%) and the CSI 300 index (0.59). The market showed a preference for defensive sectors, with chemical preparations (0.62%), traditional Chinese medicine (0.6%), and offline pharmacies (0.19%) showing minor gains, while blood products (-4.39%), other biological products (-1.78%), and vaccines (-1.49%) saw significant pullbacks [2][7]. - The GLP-1 receptor agonists are expected to catalyze growth in the weight loss drug sector. Notably, Eli Lilly announced positive results from the Phase III ACHIEVE-1 study for its oral drug Orforglipron, which is set to expand the application of GLP-1 drugs. This class of drugs is becoming a focal point for multinational corporations (MNCs) in the metabolic disease space, with domestic companies poised to benefit from rapid innovation and lower R&D costs [2][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from April 14 to April 18 showed a decline of -0.36%, with the market favoring defensive stocks. The top gainers included Shuangcheng Pharmaceutical (56.4%), Kangpeng Technology (56.3%), and Lifang Pharmaceutical (47.1%), while the largest losers were *ST Jiyuan (-50.7%), Hasanlian (-19.1%), and Changyao Holdings (-18.5%) [7][10]. Industry News and Key Company Announcements - On April 17, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in its Phase III study, showing significant reductions in A1C levels and weight loss compared to placebo [12]. - Pfizer terminated the development of its GLP-1 small molecule receptor agonist Danuglipron due to potential liver damage in trial participants [12]. - The report highlights several companies making strides in the industry, including the approval of new indications for Merck's Gardasil 9 HPV vaccine and the progress of various clinical trials for innovative drugs [13][14].

午后高位股持续下挫 连云港等多股跌停 智通财经4月15日电，午后连云港、海鸥住工、远大控股、瑞茂通跌停，回盛生物跌超10%，中源家 居、天顺股份、秋乐种业、飞力达、哈三联、凯美特气等跌幅靠前。 ...

Market Overview - The A-share market indices continued to rise, achieving a five-day consecutive increase, with a total trading volume of 1.31 trillion yuan, a decrease of 78 billion yuan from the previous trading day [1] - The Hainan sector experienced significant growth, while a few sectors such as shipping ports and the茅指数 saw declines [1] Stock Performance - A total of 103 stocks hit the daily limit, with 13 stocks achieving consecutive limit-ups, and 31 stocks failed to close at the limit, resulting in a limit-up rate of 77% (excluding ST and delisted stocks) [3] - Notable stocks included: - Guofang Group achieved a 7-day limit-up, driven by retail and brokerage investments [4] - Zhongqi New Material saw a 10.01% increase, marking its 9th day with 7 limit-ups, influenced by semiconductor equipment [4] - Zhongyuan Home achieved a limit-up, marking its 5th consecutive limit-up, supported by the sofa and e-commerce sectors [4] Institutional Trading - The top three net buying stocks on the Dragon and Tiger list were Hunan Gold, Tianhe Magnetic Materials, and Yuekang Pharmaceutical, with net purchases of 179 million yuan, 157 million yuan, and 106 million yuan, respectively [6] - The top three net selling stocks were Baolingbao, Hongbaoli, and Ouyagu, with net sales of 64.35 million yuan, 54.92 million yuan, and 46.72 million yuan, respectively [6] Sector Highlights - Hunan Gold's stock price surged due to rising gold prices, with spot gold breaking historical highs at $3,245.45 per ounce, and forecasts from Goldman Sachs and UBS predicting further increases [7] - Yuekang Pharmaceutical reported a 42.2 million yuan R&D investment in 2024, accounting for 11.16% of its revenue, reflecting a 0.78 percentage point increase year-on-year [12] - Baolingbao's stock experienced abnormal fluctuations, with a cumulative increase of over 20% in three consecutive trading days, while the company maintains a diverse product range in functional sugars [13] Notable Stock Movements - Kexing Pharmaceutical saw a significant increase of 16.83%, with a trading volume of 288 million yuan and a net institutional purchase of 89.31 million yuan [16] - Ha Sanlian's stock rose by 3.01%, with a trading volume of 787 million yuan and a net institutional purchase of 49.39 million yuan [16] - Qingdao Jinwang's stock increased by 5.41%, with a trading volume of 2.6 billion yuan and a net institutional purchase of 44.02 million yuan [16]

哈尔滨三联药业股份有限公司 关于全资子公司变更住所并完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司收到全资子公司哈尔滨三联大健康科技有限 公司的通知，其对住所进行了变更，并已完成工商变更登记手续，取得了哈尔滨 新区管理委员会行政审批局换发的《营业执照》。具体变更情况如下： 变更前： 住所：哈尔滨市松北区江平街 444 号 变更后： 证券代码：002900 证券简称：哈三联 公告编号：2025-013 2025 年 04 月 10 日 哈尔滨三联药业股份有限公司 董事会 住所：黑龙江省哈尔滨市利民开发区北京路中段 除住所变更外，哈尔滨三联大健康科技有限公司《营业执照》的其他登记事 项均保持不变。 备查资料 1、哈尔滨三联大健康科技有限公司营业执照。 特此公告。 ...

东海证券认为，近期多家创新药上市公司披露业绩数据优秀，行业政策持续回暖，带动创新药、医疗服 务等板块关注度持续提升。上周五，我国发布对美加征关税的系列反制，其中CT等医疗设备在列，预 期随着关税战持续，整体高端医疗装备、血制品等领域国产替代有望进一步提速。此外，医疗服务、连 锁药店、中药等领域主要面向国内本土市场，整体几乎不受贸易战影响，板块韧性强。当前医药板块整 体投资配置价值显著，随着上市公司进入业绩密集披露期，建议关注经营稳健，业绩边际持续向好，现 金流充沛的优质公司。建议关注创新药链、医疗服务、连锁药店、器械设备、品牌中药、血制品等细分 板块及个股的投资机会。 上周，特朗普宣布的针对美国进口商品的广泛关税未涉及药品，但他表示药品将面临单独的关税。 机构表示，市场对于关税对医药板块的影响存在过度担忧、目前超跌严重，但情绪波动或许将在短期内 持续。考虑到下半年医保丙类目录等利好政策有望正式落地、板块回调后估值仍处历史低位。 医药板块9日盘中大幅下挫，截至发稿，多瑞医药（301075）、翰宇药业（300199）、诚达药业 （301201）等跌超10%，哈三联（002900）、润都股份（002923）跌停，鲁 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [35]. Core Insights - The pharmaceutical and biotechnology sector showed a 1.20% increase in performance from March 31 to April 3, ranking third among 31 industries and outperforming the CSI 300 index by 2.57 percentage points [11][16]. - Year-to-date, the sector has risen by 4.77%, ranking seventh among 31 industries and surpassing the CSI 300 index by 6.64 percentage points [16]. - The current PE valuation for the pharmaceutical and biotechnology sector stands at 27.2 times, which is at a historically low level, with a 130% premium compared to the CSI 300 index [20]. Market Performance - The top three sub-sectors in terms of growth last week were chemical pharmaceuticals (3.45%), traditional Chinese medicine II (1.53%), and pharmaceutical commerce (1.48%) [11]. - A total of 344 stocks (72.57% of the sector) experienced price increases last week, with the top five performers being Duorui Pharmaceutical (56.32%), Weisi Medical (31.80%), Hasanlian (31.15%), Rundu Co. (27.01%), and Shengnuo Biological (21.54%) [25][26]. Industry News - On April 4, the Ministry of Commerce announced investigations into the competitiveness of imported medical CT tubes and initiated anti-dumping investigations against imports from the United States and India [27][30]. - The investigations will assess the impact of these imports on the domestic industry and its competitiveness, covering the period from January 1, 2024, to December 31, 2024, for dumping and from January 1, 2022, to December 31, 2024, for industry damage [29][30]. Investment Recommendations - The report suggests focusing on sectors such as innovative drugs, medical services, and domestic market-oriented businesses, which are less affected by trade frictions [31]. - It highlights the potential for accelerated domestic substitution in high-end medical equipment and blood products due to ongoing tariff disputes [31]. - Recommended stocks include Beida Pharmaceutical, Laobaixing, Lingrui Pharmaceutical, Huaxia Eye Hospital, and Boya Biological, with additional stocks to watch being Tebao Biological, Kelun Pharmaceutical, International Medicine, Kaili Medical, and Nuotai Biological [32].